文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性的早期检测:基于EDNA研究数据的经济学评价

Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study.
PubMed 文献 · Br J Ophthalmol · 2021-08-02

本研究基于英国EDNA研究数据,构建患者水平状态转移模型,模拟单侧nAMD治疗患者对侧眼nAMD的发生、检测和治疗,比较五种监测测试的成本效果。

要点

  • SD-OCT监测对侧眼nAMD较其他测试产生更多QALYs且成本更低。
  • SD-OCT阳性经FFA确认后早期治疗可维持更好视力与生活质量。

核心结论

  • SD-OCT阳性经FFA确认后早期治疗对侧眼,预期可维持更好视力和健康相关生活质量,并可能降低终生健康与社会护理成本。

研究设计与样本

  • 基于英国EDNA研究数据构建患者水平状态转移模型,模拟单侧nAMD治疗患者对侧眼nAMD的发生、检测和治疗,时间跨度25年。

主要发现

  • SD-OCT产生QALYs为5.830,高于眼底评估5.787、Amsler格5.736、患者主观评估5.630和视力5.600。

关键数值与推荐

  • 比较的五种指标测试包括:自我报告视功能变化、Amsler测试、临床测量视力较基线变化、临床检查或彩色摄影眼底评估、SD-OCT。
  • nAMD诊断需经FFA确认后及时启动抗VEGF治疗。

临床怎么用

  • 在NHS门诊环境中,对单侧nAMD治疗患者对侧眼监测时,SD-OCT可能是更具成本效果的检测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the cost-effectiveness of non-invasive monitoring tests to detect the onset of neovascular age-related macular degeneration (nAMD) in the unaffected second eye of patients receiving treatment for unilateral nAMD in a UK National Health Service (NHS) hospital outpatient setting. METHODS: A patient-level state transition model was constructed to simulate the onset, detection, and treatment of nAMD in the second eye. Five index tests were compared: self-reported change in visual function, Amsler test, clinic measured change in visual acuity from baseline, fundus assessment by clinical examination or colour photography, and spectral domain optical coherence tomography (SD-OCT). Diagnosis of nAMD was confirmed by fundus fluorescein angiography (FFA) before prompt initiation of antivascular endothelial growth factor treatment. Quality-adjusted life-years (QALYs) and costs of health and social care were modelled over a 25-year time horizon. RESULTS: SD-OCT generated more QALYs (SD-OCT, 5.830; fundus assessment, 5.787; Amsler grid, 5.736, patient's subjective assessment, 5.630; and visual acuity, 5.600) and lower health and social care costs (SD-OCT, £19 406; fundus assessment, £19 649; Amsler grid, £19 751; patient's subjective assessment, £20 198 and visual acuity, £20 444) per patient compared with other individual monitoring tests. Probabilistic sensitivity analysis indicated a high probability (97%-99%) of SD-OCT being the preferred test across a range of cost-effectiveness thresholds (£13 000-£30 000) applied in the UK NHS. CONCLUSIONS: Early treatment of the second eye following FFA confirmation of SD-OCT positive findings is expected to maintain better visual acuity and health-related quality of life and may reduce costs of health and social care over the lifetime of patients.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hernandez R, Kennedy C, Banister K, et al. Early detection of neovascular age-related macular degeneration: an economic evaluation based on data from the EDNA study. Br J Ophthalmol. 2021. PMID: 34340976. doi:10.1136/bjophthalmol-2021-319506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。